Digest Network Come funziona
Network
/
Società
Ne
Non verificato

Neuraptive Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIgiene alimentareIndustriaSalute

2 comunicati stampa

Guarda tutti i comunicati
02/10/2025
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Difesa / Forze Armate
Industria
Neuraptive Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating the Safety and Efficacy of NTX-001 Compared to Standard of Care in the Treatment of Upper Extremity Transected Nerves Requiring Surgical Repair
Fonte
Neuraptive Therapeutics, Inc.
Emittente
Business Wire
1.00
0
11/09/2024
Neuraptive Therapeutics Receives FDA Breakthrough Therapy Designation for NTX-001 and Provides Update on the Advancements of NTX-001 for the Treatment of Peripheral Nerve Injury Requiring Repair
Fonte
Neuraptive Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0